Difference between revisions of "Vascular sarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only." to "Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.") |
Warner-admin (talk | contribs) m (Text replacement - "https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf" to "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464") |
||
| Line 19: | Line 19: | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
| − | *[https://www.nccn.org/ | + | *[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1464 NCCN Guidelines - Soft Tissue Sarcoma] |
=Hemangioendothelioma, all lines of therapy= | =Hemangioendothelioma, all lines of therapy= | ||
=Hemangiopericytoma (solitary fibrous tumor), all lines of therapy= | =Hemangiopericytoma (solitary fibrous tumor), all lines of therapy= | ||
Revision as of 19:25, 7 May 2024
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
0 regimens on this page
0 variants on this page
|
Note: this page does not contain any regimens. The following links will take you to disease-specific pages with regimens:
- Regimens for Angiosarcoma are here.
- Regimens for Kaposi sarcoma are here.
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
ESMO
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) PubMed